Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N2O2 |
Molecular Weight | 146.1876 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(O)=O
InChI
InChIKey=KDXKERNSBIXSRK-YFKPBYRVSA-N
InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1
Molecular Formula | C6H14N2O2 |
Molecular Weight | 146.1876 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.nap.edu/read/10490/chapter/12Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.
CNS Activity
Originator
Sources: https://www.drugs.com/npp/lysine.html
Curator's Comment: Lysine was first isolated from casein (a milk phosphoprotein) in 1889 by the German dentist Heinrich Drechsel
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616 |
|||
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | L-LYSINE MONOHYDRATE Approved UseLysine has been studied for the prevention and treatment of herpes infections and cold sores. |
|||
Primary | L-LYSINE MONOHYDRATE Approved UseLysine supplements may relieve effort-related angina pectoris. |
|||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine increases the intestinal absorption and reduces the renal elimination of calcium. |
||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist |
||
Palliative | L-LYSINE MONOHYDRATE Approved UseLysine acetylsalicylate has been used to detoxify the body after heroin use. |
|||
Primary | NEOPROFEN Approved UseNeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. | 2001 |
|
The antioxidant system beta-D(+) glucose-glucose oxidase-catalase: tests for pyrogenicity and antigenicity. | 2001 |
|
Protein profiling comes of age. | 2001 |
|
Identification of the alpha-aminoadipic semialdehyde dehydrogenase-phosphopantetheinyl transferase gene, the human ortholog of the yeast LYS5 gene. | 2001 Apr |
|
Differences in sialic acid density in pathogenic and non-pathogenic Aspergillus species. | 2001 Apr |
|
Formation of 1,1'-iminodicarboxylic acid derivatives, 2,6-diketo-piperazine and dibenzodiazocine-2,6-dione by variations of multicomponent reactions. | 2001 Apr |
|
The fermentative production of L-lysine as an animal feed additive. | 2001 Apr |
|
Translational extracts active biologically in vitro obtained from eukaryotic monolayer cells: a versatile method for viral RNA studies. | 2001 Apr |
|
Effect of the degree of fatty acid unsaturation of rat heart mitochondria on their rates of H2O2 production and lipid and protein oxidative damage. | 2001 Apr 15 |
|
The number of morphological synapses between neurons does not predict the strength of their physiological synaptic interactions: a study of dendrites in the nematode Ascaris suum. | 2001 Apr 16 |
|
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli. | 2001 Apr 17 |
|
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. | 2001 Apr 27 |
|
Ethanol production from wheat straw hemicellulose hydrolysate by Pichia stipitis. | 2001 Apr 27 |
|
Biochemical and functional characterization of a molecule expressed by a subset of thymic medullary epithelial cells. | 2001 Feb |
|
Isolation of the Escherichia coli nucleoid. | 2001 Feb |
|
Detection of early gene expression changes during activation of human primary lymphocytes by in vitro synthesis of proteins from polysome-associated mRNAs. | 2001 Feb |
|
The effect of protease inhibitors on the two-dimensional electrophoresis pattern of red blood cell membranes. | 2001 Feb |
|
In vivo distribution and speciation of [114mIn]InCl3 in the Wistar rat. | 2001 Feb |
|
L-lysine reduces nonenzymatic glycation of glomerular basement membrane collagen and albuminuria in diabetic rats. | 2001 Feb |
|
Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. | 2001 Feb |
|
Hydrolysed protein accelerates the gastrointestinal transport of formula in preterm infants. | 2001 Feb |
|
Combination of HPLC and solid-phase binding assay for isolation and purification of MHC class I and associated peptides using a bladder tumour cell line. | 2001 Feb |
|
Identification of novel hypocholesterolemic peptides derived from bovine milk beta-lactoglobulin. | 2001 Feb 16 |
|
Identification of a candidate integrin-fraction associated with the activated form of the PDGF-receptor. | 2001 Feb 23 |
|
Uptake and accumulation of exogenous docosahexaenoic acid by Chlorella. | 2001 Jan |
|
Endotoxemia and acute-phase proteins in major abdominal surgery. | 2001 Jan |
|
Influence of lysates of the salivary glands of Lutzomyia longipalpis on the development of a Leishmania-major-like parasite in the skin of the golden hamster. | 2001 Jan |
|
ESR detection of intraphagosomal superoxide in polymorphonuclear leukocytes using 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide. | 2001 Jan |
|
A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins. | 2001 Jan |
|
Inhibition of the nitrosothiol production of cultured osteoarthritic chondrocytes by rhein, cortisol and diclofenac. | 2001 Jan |
|
Continuous cell introduction for the analysis of individual cells by capillary electrophoresis. | 2001 Jan 1 |
|
A single-chain variable region immunoglobulin library from the abomasal lymph node of sheep infected with the gastrointestinal nematode parasite Haemonchus contortus. | 2001 Jan 26 |
|
Purification of recombinant green fluorescent protein using chromatofocusing with a pH gradient composed of multiple stepwise fronts. | 2001 Jan-Feb |
|
Endogenous formation of protein adducts with carcinogenic aldehydes: implications for oxidative stress. | 2001 Jun 29 |
|
Chemical and biological evaluation of endotoxin contamination on natural rubber latex products. | 2001 Jun 5 |
|
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. | 2001 Mar |
|
Mechanisms of photoreceptor cell death in cancer-associated retinopathy. | 2001 Mar |
|
Post-transcriptional effects of extracellular pH on tumour necrosis factor-alpha production in RAW 246.7 and J774 A.1 cells. | 2001 Mar |
|
Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. | 2001 Mar 1 |
|
Quantitative analysis of specific mRNA species in minute cell samples by RT-PCR and flow cytometry. | 2001 Mar 1 |
|
Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder. | 2001 Mar 14 |
|
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. | 2001 Mar 15 |
|
Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. | 2001 Mar 15 |
|
High pressure increases bactericidal activity and spectrum of lactoferrin, lactoferricin and nisin. | 2001 Mar 20 |
|
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. | 2001 Mar 21 |
|
Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytanoyl-CoA alpha-hydroxylase-associated protein 1, a novel BAI1-binding protein. | 2001 Mar 5 |
|
Western blotting as a method for studying cell-biomaterial interactions: the role of protein collection. | 2001 Mar 5 |
|
Influence of crystal shape on the tableting performance of L-lysine monohydrochloride dihydrate. | 2001 May |
|
Isolation and characterization of senescence-induced cDNAs encoding deoxyhypusine synthase and eucaryotic translation initiation factor 5A from tomato. | 2001 May 18 |
|
The heme-regulated eukaryotic initiation factor 2alpha kinase. A potential regulatory target for control of protein synthesis by diffusible gases. | 2001 May 4 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.nap.edu/read/10490/chapter/12
Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616
In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:35:16 GMT 2025
by
admin
on
Mon Mar 31 17:35:16 GMT 2025
|
Record UNII |
K3Z4F929H6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
32256-0
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
56955-8
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
22651-4
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
15140-7
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
WHO-VATC |
QB05XB03
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
13375-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
2587-4
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
13769-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
2586-6
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47689-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
20650-8
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47693-7
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47694-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
22713-2
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47692-9
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
25952-3
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47695-2
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
WHO-ATC |
B05XB03
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
44335-8
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
2585-8
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
30048-3
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
13404-9
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
15136-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
55935-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
88018-7
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
DSLD |
172 (Number of products:1388)
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
27333-4
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
WHO-VATC |
QA12AA09
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
17230-4
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
27107-2
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
25464-9
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
JECFA EVALUATION |
1439
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
32255-2
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
2584-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
22679-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
CFR |
21 CFR 310.537
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
27304-5
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
25953-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47690-3
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
LOINC |
47691-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2108
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
6166
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
DB00123
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
m6967
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB36688
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
200-294-2
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
133538
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
1427
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
SUB08629MIG
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
K3Z4F929H6
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
100000091077
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
5962
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
DTXSID6023232
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
56-87-1
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
K3Z4F929H6
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
18019
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL8085
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
1622
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
29967
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
C29171
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
LYSINE
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
6536
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
32551
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
D008239
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY | |||
|
25094
Created by
admin on Mon Mar 31 17:35:16 GMT 2025 , Edited by admin on Mon Mar 31 17:35:16 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
RACEMATE -> ENANTIOMER | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|